Onderzoeker
Robert Paridaens
- Disciplines:Laboratoriumgeneeskunde, Palliatieve zorg en zorg rond het levenseinde, Regeneratieve geneeskunde, Andere basiswetenschappen, Andere gezondheidswetenschappen, Verpleegkunde, Andere paramedische wetenschappen, Andere translationele wetenschappen, Andere medische en gezondheidswetenschappen
Affiliaties
- Laboratorium Experimentele Oncologie (Afdeling)
Lid
Vanaf1 okt 2005 → 30 sep 2017
Publicaties
1 - 10 van 121
- Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials(2020)
Auteurs: Robert Paridaens
Pagina's: 3273 - + - Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics(2019)
Auteurs: Robert Paridaens
Pagina's: 383 - 393 - Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer(2019)
Auteurs: Laurence Slembrouck, Siel Olbrecht, Lynn Jongen, Hans Wildiers, Giuseppe Floris, Erik Van Limbergen, Caroline Weltens, Ann Smeets, Robert Paridaens, Ignace Vergote, et al.
Pagina's: 165 - 171 - Tamoxifen metabolism and efficacy in breast cancer– a prospective multicentre trial(2018)
Auteurs: Patrick Neven, Lynn Jongen, Diether Lambrechts, Hans Wildiers, Maria-Reinhilde Casteels, Sabine Van Huffel, Robert Paridaens, Ignace Vergote, Ben Van Calster
Pagina's: 1 - 19 - Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study(2018)
Auteurs: Annouschka Laenen, Adelheid Soubry, Ann Smeets, Ignace Vergote, Hans Wildiers, Robert Paridaens, Erik Van Limbergen, Caroline Weltens, Philippe Moerman, Giuseppe Floris, et al.
Pagina's: 189 - 196 - Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials(2018)
Auteurs: Marie-Rose Christiaens, Patrick Neven, Robert Paridaens, Walter Van den Bogaert
Pagina's: 27 - 39 - Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial(2017)
Auteurs: Robert Paridaens
Pagina's: 1211 - 1220 - Long-Term Follow-Up of the Intergroup Exemestane Study(2017)
Auteurs: Robert Paridaens
Pagina's: 2507 - + - Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm(2016)
Auteurs: Lynn Jongen, Robert Paridaens, Giuseppe Floris, Hans Wildiers, Patrick Neven
Pagina's: 603 - 7 - Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients(2015)
Auteurs: Charlotte Maggen, Diether Lambrechts, Sigrid Hatse, Patrick Neven, Robert Paridaens, Hans Wildiers
Pagina's: 67 - 76